Ingelvac PRRS MLV
Ingelvac PRRS MLV
Ingelvac PRRS MLV
Ingelvac PRRS MLV
Boehringer Ingelheim Animal Health USA, Inc.

Ingelvac PRRS® MLV, 250 Dose

As compared to Prevacent PRRS, Fostera PRRS or PRRSGard

Category: Vaccines, Big Order Discount Eligible

Species: Swine

Active Ingredient(s): porcine reproductive and respiratory syndrome virus (PRRS-respiratory form); porcine reproductive and respiratory syndrome virus (PRRS-reproductive form)


FBN PRICE

$249.11 ($1.00/dose)



Shipping

Estimated delivery to choose your location by: N/A

* Update your zip code to get an estimate

Potential delays for this product

Refrigeration required

Product details

INGELVAC PRRS MLV, a leading modified-live porcine reproductive and respiratory syndrome (PRRS) vaccine, has been trusted for over 25 years to protect the swine industry against reproductive and respiratory symptoms of PRRSv.    

INGELVAC PRRS MLV is a modified-live PRRS vaccine that is proven safe in pigs as well as gilts and sows at any stage of production in PRRS-positive herds. It provides cross-protection against heterologous challenge (including Lineage 1 viruses), and has been shown to significantly reduce reproductive failure and respiratory disease due to PRRS virus.  

Features & Benefits

  • Demonstrated Heterologous Cross-Protection  INGELVAC PRRS MLV has demonstrated significant cross-protection against the most current relevant heterologous wild-type PRRS virus strains and continues to be evaluated in order to provide you with the most up-to-date information.

  • Whole-Herd Approach (Use at any stage of production)  INGELVAC PRRS MLV is the only vaccine that has demonstrated proven efficacy and safety in all stages and phases of production. So, mass vaccination or population-based protocols are recommended for building and maintaining whole-herd immunity.  

  • Consistent and Repeatable Direct and Indirect Benefits  

DIRECT BENEFIT: Multiple controlled and field-based studies have demonstrated that INGELVAC PRRS MLV mitigates the consequences of infection; it reduces clinical disease and provides biologic benefit, thus improving health and performance. 

INDIRECT BENEFIT: Studies have also shown vaccination with INGELVAC PRRS MLV contributes to reduced magnitude and duration of viremia, as well as reduced shedding of wild-type PRRSV within and from vaccinated populations, leading to a reduction in the challenge risk and infection pressure within and between vaccinated herds and populations.   

  • Complete PRDC Protocol (Most extensive PRRS vaccine line)  INGELVAC PRRS MLV is the only PRRS vaccine licensed by the USDA for use in the widest range of combinations (for example: 3FLEX®, FLEXcircoPRRS® and FLEXmycoPRRS®) to best meet the needs of your protocol and operation. 

Ingelvac PRRS® is a registered trademark of Boehringer Ingelheim Animal Health USA, Inc.

Similar Products
Same Active, Same Concentration

No products with same active, same concentration

Same Active, Different Concentration

No products with same active, different concentration

Same Mode of Action, Different Active

No products with same mode of action, different active